Company news
Lotus Pharmaceutical Co., Ltd. (TWSE:1795) news
Lotus Pharmaceutical Co., Ltd. news releases on 6ix. Latest, May 22, 2026: Lotus Pharmaceutical Announces Acquisition of a Specialty Pharmaceutical Product…
Press releases & updates
Lotus Pharmaceutical Announces Acquisition of a Specialty Pharmaceutical Product in South Korea, Expanding Portfolio in Urology and Infectious Disease Prevention
May 22, 2026
Lotus Reports October 2025 Revenue of NT$2,753 Million
November 11, 2025
Lotus Enters License and Supply Agreement with Adalvo for Semaglutide injection
October 6, 2025
Alvogen Announces Sale to Lotus, Creating a Leading International Specialized Generics Platform
September 23, 2025
Lotus Pharmaceutical reports August 2025 Revenue of NT$1,160 Million
September 11, 2025
Lotus reports July 2025 Revenue of NT$2,397 Million
August 12, 2025
Lotus reports June 2025 Revenue of NT$1,044 Million
July 11, 2025
Lotus Announces TFDA Approval for Adcirca for PAH Treatment
February 12, 2025
Lotus Announces the Closing of the Alphachymotrypsine Choay Acquisition, Ready to consolidate revenue from Q1 2025
January 8, 2025
Lotus Reported Unaudited November Revenues of NT$1,061 million, YTD Revenue Surpassing the Total Revenue for 2023
December 11, 2024
Lotus Reported Unaudited September Revenues of NT$1,187 million
October 14, 2024
Lotus Reported Unaudited July Revenues of NT$2,722 million, second-highest monthly revenue in the company's history
August 12, 2024
Lotus Pharmaceutical Honored 2024 Taiwan BIO Awards- Outstanding Company of the Year, Showcasing Excellence in Operational Performance, Development Strategy, and Technological Innovation
July 29, 2024
Lotus Reported Unaudited December Consolidated Revenues of NT$1,372 million, showcasing MoM and YoY Growth 2023 Unaudited Consolidated Revenues Grew 16% to NT$16,958 million, marking 5th consecutive year of double-digit growth
January 11, 2024
Lotus Pharmaceutical Co., Ltd. Reports Solid Financial Results for September 2023 and Year-to-Date Growth
October 12, 2023
Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia
August 10, 2023
Lotus partners with Eurofarma & Adalvo, launching Nuvyor (Lenalidomide) in Brazil, indicated in the treatment of multiple myeloma
February 2, 2023
Lotus Obtains Tentative Approval for Nintedanib ANDA from the US FDA
January 16, 2023
LOTUS REPORTS ITS BEST QUARTER EVER WITH THE BIGGEST LAUNCH IN ITS HISTORY
November 11, 2022
Lotus Launches Lenalidomide Capsules 5mg, 10mg, 15mg, and 25mg, Generic Version of Revlimid in the US
September 5, 2022
Lotus Receives Tentative Approval for Midostaurin ANDA from the US FDA
August 26, 2022